| (Values in U.S. Thousands) | Oct, 2017 | Jul, 2017 | Apr, 2017 | Jan, 2017 | Oct, 2016 |
| Sales | 12,780 | 27,080 | 17,900 | 10,750 | 23,370 |
| Sales Growth | -52.81% | +51.28% | +66.51% | -54.00% | +316.58% |
| Net Income | -12,620 | -1,210 | -5,270 | -7,770 | -4,060 |
| Net Income Growth | -942.98% | +77.04% | +32.18% | -91.38% | +63.29% |
Peregrine Pharma New (PPHM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus infection. The company is pursuing three separate clinical trials in cancer and HCV infection with its lead product candidate bavituximab and Cotara. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and bio-manufacturing services for both Peregrine and outside customers.